Autonomix Medical wins new US patent for nerve-sensing cancer treatment systems

Autonomix Medical received U.S. Patent No. 12,433,670 for systems and methods to treat cancer or augment organ function.

The patent covers minimally invasive catheter-based tools to sense and map nerve activity, then guide targeted neuromodulation or delivery of therapeutic agents.

Protection extends to selectively targeting tumor-associated nerves linked to cancer-related pain, organ function and autonomic nervous system disorders.

The company highlighted potential use across solid tumors such as pancreatic, prostate and breast cancers.